ZA200401260B - 6,7-dihydro-5h-pyrazol(1,2-a)pyrazol-1-ones which control inflammatory cytokines. - Google Patents
6,7-dihydro-5h-pyrazol(1,2-a)pyrazol-1-ones which control inflammatory cytokines. Download PDFInfo
- Publication number
- ZA200401260B ZA200401260B ZA200401260A ZA200401260A ZA200401260B ZA 200401260 B ZA200401260 B ZA 200401260B ZA 200401260 A ZA200401260 A ZA 200401260A ZA 200401260 A ZA200401260 A ZA 200401260A ZA 200401260 B ZA200401260 B ZA 200401260B
- Authority
- ZA
- South Africa
- Prior art keywords
- fluorophenyl
- dihydro
- substituted
- pyrazolo
- pyrimidin
- Prior art date
Links
- 102000004127 Cytokines Human genes 0.000 title claims description 19
- 108090000695 Cytokines Proteins 0.000 title claims description 19
- 230000002757 inflammatory effect Effects 0.000 title claims description 13
- -1 2,6-difluorophenyl Chemical group 0.000 claims description 117
- 229910052739 hydrogen Inorganic materials 0.000 claims description 75
- 239000001257 hydrogen Substances 0.000 claims description 74
- 150000001875 compounds Chemical class 0.000 claims description 51
- 239000000203 mixture Substances 0.000 claims description 50
- 125000000217 alkyl group Chemical group 0.000 claims description 42
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 36
- 150000002431 hydrogen Chemical class 0.000 claims description 36
- 125000003118 aryl group Chemical group 0.000 claims description 31
- 125000000623 heterocyclic group Chemical group 0.000 claims description 25
- 125000001072 heteroaryl group Chemical group 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 22
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 18
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 17
- 125000004429 atom Chemical group 0.000 claims description 15
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 15
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 14
- 125000002837 carbocyclic group Chemical group 0.000 claims description 14
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 14
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 11
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 150000001768 cations Chemical class 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 125000005275 alkylenearyl group Chemical group 0.000 claims description 7
- 125000005218 alkyleneheteroaryl group Chemical group 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 6
- 125000001033 ether group Chemical group 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 5
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims description 5
- STUHQDIOZQUPGP-UHFFFAOYSA-N morpholin-4-ium-4-carboxylate Chemical compound OC(=O)N1CCOCC1 STUHQDIOZQUPGP-UHFFFAOYSA-N 0.000 claims description 5
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 4
- FIRLRGSIGYHQMD-UHFFFAOYSA-N 6-(4-fluorophenyl)-7-(2-phenoxypyrimidin-4-yl)-2,3-dihydro-1h-pyrazolo[1,2-a]pyrazol-5-one Chemical compound C1=CC(F)=CC=C1C(C(N1CCCN11)=O)=C1C1=CC=NC(OC=2C=CC=CC=2)=N1 FIRLRGSIGYHQMD-UHFFFAOYSA-N 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 229940051880 analgesics and antipyretics pyrazolones Drugs 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 125000004353 pyrazol-1-yl group Chemical group [H]C1=NN(*)C([H])=C1[H] 0.000 claims description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 9
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 8
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 5
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 5
- 229920002554 vinyl polymer Polymers 0.000 claims 5
- ZYHQGITXIJDDKC-UHFFFAOYSA-N 2-[2-(2-aminophenyl)ethyl]aniline Chemical group NC1=CC=CC=C1CCC1=CC=CC=C1N ZYHQGITXIJDDKC-UHFFFAOYSA-N 0.000 claims 4
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 4
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims 4
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 4
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 3
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 claims 3
- VZVQZEWVRSRUJJ-UHFFFAOYSA-N 1h-pyrazolo[1,2-a]pyrazol-5-one Chemical compound C1C=CN2C(=O)C=CN21 VZVQZEWVRSRUJJ-UHFFFAOYSA-N 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 101
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 96
- 239000000243 solution Substances 0.000 description 79
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 78
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 72
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 51
- 238000002360 preparation method Methods 0.000 description 44
- 238000006243 chemical reaction Methods 0.000 description 42
- 239000000047 product Substances 0.000 description 42
- 239000003153 chemical reaction reagent Substances 0.000 description 40
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 36
- 235000019439 ethyl acetate Nutrition 0.000 description 36
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 29
- ZMXDDKWLCZADIW-UHFFFAOYSA-N Vilsmeier-Haack reagent Natural products CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- 238000003756 stirring Methods 0.000 description 23
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 22
- 239000000377 silicon dioxide Substances 0.000 description 22
- 239000007787 solid Substances 0.000 description 22
- 239000003921 oil Substances 0.000 description 21
- 235000019198 oils Nutrition 0.000 description 21
- 239000012044 organic layer Substances 0.000 description 21
- 239000000543 intermediate Substances 0.000 description 19
- 239000010410 layer Substances 0.000 description 16
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 14
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 14
- 239000011541 reaction mixture Substances 0.000 description 14
- 229910000104 sodium hydride Inorganic materials 0.000 description 14
- 150000002170 ethers Chemical class 0.000 description 13
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 239000000725 suspension Substances 0.000 description 11
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 10
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 10
- 125000003277 amino group Chemical group 0.000 description 10
- 239000012267 brine Substances 0.000 description 10
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 239000007864 aqueous solution Substances 0.000 description 9
- 239000012043 crude product Substances 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 7
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 7
- ANGFERNLRQXLRG-UHFFFAOYSA-N benzyl 2-[2-(4-fluorophenyl)acetyl]-4-oxopyrazolidine-1-carboxylate Chemical compound C1=CC(F)=CC=C1CC(=O)N1N(C(=O)OCC=2C=CC=CC=2)CC(=O)C1 ANGFERNLRQXLRG-UHFFFAOYSA-N 0.000 description 7
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 239000008346 aqueous phase Substances 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- ZIBBYQDOFMVSTR-UHFFFAOYSA-N 1-o-benzyl 2-o-tert-butyl 4-methylidenepyrazolidine-1,2-dicarboxylate Chemical compound CC(C)(C)OC(=O)N1CC(=C)CN1C(=O)OCC1=CC=CC=C1 ZIBBYQDOFMVSTR-UHFFFAOYSA-N 0.000 description 5
- ISQQEOJMKNIJEL-UHFFFAOYSA-N 2-phenoxypyrimidine-4-carbonyl chloride Chemical compound ClC(=O)C1=CC=NC(OC=2C=CC=CC=2)=N1 ISQQEOJMKNIJEL-UHFFFAOYSA-N 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 239000013058 crude material Substances 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- XGAKJVDFGWJLBN-UHFFFAOYSA-N 6-(4-fluorophenyl)-7-(2-methylsulfonylpyrimidin-4-yl)-2,3-dihydro-1h-pyrazolo[1,2-a]pyrazol-5-one Chemical compound CS(=O)(=O)C1=NC=CC(C=2N3CCCN3C(=O)C=2C=2C=CC(F)=CC=2)=N1 XGAKJVDFGWJLBN-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 102000000589 Interleukin-1 Human genes 0.000 description 4
- 108010002352 Interleukin-1 Proteins 0.000 description 4
- CRZQGDNQQAALAY-UHFFFAOYSA-N Methyl benzeneacetate Chemical compound COC(=O)CC1=CC=CC=C1 CRZQGDNQQAALAY-UHFFFAOYSA-N 0.000 description 4
- FLZJCIJETJDKHZ-UHFFFAOYSA-N benzyl 2-[2-(4-fluorophenyl)acetyl]-4-methylidenepyrazolidine-1-carboxylate Chemical compound C1=CC(F)=CC=C1CC(=O)N1N(C(=O)OCC=2C=CC=CC=2)CC(=C)C1 FLZJCIJETJDKHZ-UHFFFAOYSA-N 0.000 description 4
- ZXPWSWRNPBDBGH-UHFFFAOYSA-N benzyl 4-methylidenepyrazolidine-1-carboxylate Chemical compound C1C(=C)CNN1C(=O)OCC1=CC=CC=C1 ZXPWSWRNPBDBGH-UHFFFAOYSA-N 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- NWEKLKAEZPSPGG-UHFFFAOYSA-N methyl 2-(4-fluorophenyl)-3-(2-methylsulfanylpyrimidin-4-yl)-3-oxopropanoate Chemical compound C=1C=C(F)C=CC=1C(C(=O)OC)C(=O)C1=CC=NC(SC)=N1 NWEKLKAEZPSPGG-UHFFFAOYSA-N 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- JPDCNXBSQDNBDS-UHFFFAOYSA-N 1-[4-(dimethylamino)pyrazolidin-1-yl]-2-(4-fluorophenyl)ethanone Chemical compound C1C(N(C)C)CNN1C(=O)CC1=CC=C(F)C=C1 JPDCNXBSQDNBDS-UHFFFAOYSA-N 0.000 description 3
- XCQBXQWVOZDGTH-UHFFFAOYSA-N 2-phenoxypyrimidine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC(OC=2C=CC=CC=2)=N1 XCQBXQWVOZDGTH-UHFFFAOYSA-N 0.000 description 3
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- ANEDSOHLDQAVDN-UHFFFAOYSA-N [1-[2-(4-fluorophenyl)acetyl]-2-phenylmethoxycarbonylpyrazolidin-4-yl] morpholine-4-carboxylate Chemical compound C1=CC(F)=CC=C1CC(=O)N1N(C(=O)OCC=2C=CC=CC=2)CC(OC(=O)N2CCOCC2)C1 ANEDSOHLDQAVDN-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- FJESTSZQODSANC-UHFFFAOYSA-N methyl 2-(4-fluorophenyl)-3-hydroxy-3-(2-methylsulfanylpyrimidin-4-yl)propanoate Chemical compound C=1C=C(F)C=CC=1C(C(=O)OC)C(O)C1=CC=NC(SC)=N1 FJESTSZQODSANC-UHFFFAOYSA-N 0.000 description 3
- NWDADIBYIHDSHF-UHFFFAOYSA-N methyl 2-methylsulfonylpyrimidine-4-carboxylate Chemical compound COC(=O)C1=CC=NC(S(C)(=O)=O)=N1 NWDADIBYIHDSHF-UHFFFAOYSA-N 0.000 description 3
- ONLQTQQQTMANMX-UHFFFAOYSA-N methyl 2-phenoxypyrimidine-4-carboxylate Chemical compound COC(=O)C1=CC=NC(OC=2C=CC=CC=2)=N1 ONLQTQQQTMANMX-UHFFFAOYSA-N 0.000 description 3
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 2
- SCFGHDIKKZVWMU-UHFFFAOYSA-N 1-o-benzyl 2-o-tert-butyl 4-(2,2-dimethylpropanoyloxy)pyrazolidine-1,2-dicarboxylate Chemical compound CC(C)(C)OC(=O)N1CC(OC(=O)C(C)(C)C)CN1C(=O)OCC1=CC=CC=C1 SCFGHDIKKZVWMU-UHFFFAOYSA-N 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- QGJXHPACBLAFFJ-UHFFFAOYSA-N 2-methylsulfanylpyrimidine-4-carbaldehyde Chemical compound CSC1=NC=CC(C=O)=N1 QGJXHPACBLAFFJ-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- PZVWKCGKIADPAU-UHFFFAOYSA-N 4-(1,3-benzothiazol-2-ylsulfanyl)aniline Chemical compound C1=CC(N)=CC=C1SC1=NC2=CC=CC=C2S1 PZVWKCGKIADPAU-UHFFFAOYSA-N 0.000 description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- AKLKEMALKIMWBQ-UHFFFAOYSA-N 6-(4-fluorophenyl)-2-hydroxy-7-(2-phenoxypyrimidin-4-yl)-2,3-dihydro-1h-pyrazolo[1,2-a]pyrazol-5-one Chemical compound O=C1N2CC(O)CN2C(C=2N=C(OC=3C=CC=CC=3)N=CC=2)=C1C1=CC=C(F)C=C1 AKLKEMALKIMWBQ-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 229910004373 HOAc Inorganic materials 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- AIJULSRZWUXGPQ-UHFFFAOYSA-N Methylglyoxal Chemical compound CC(=O)C=O AIJULSRZWUXGPQ-UHFFFAOYSA-N 0.000 description 2
- 239000012425 OXONE® Substances 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- HVJGDUTWIXHXAD-UHFFFAOYSA-N [1-[2-(4-fluorophenyl)acetyl]-2-(2-phenoxypyrimidine-4-carbonyl)pyrazolidin-4-yl] morpholine-4-carboxylate Chemical compound C1=CC(F)=CC=C1CC(=O)N1N(C(=O)C=2N=C(OC=3C=CC=CC=3)N=CC=2)CC(OC(=O)N2CCOCC2)C1 HVJGDUTWIXHXAD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- ZUTIOUJGTRXZOF-UHFFFAOYSA-N benzyl 2-[2-(4-fluorophenyl)acetyl]-4-hydroxypyrazolidine-1-carboxylate Chemical compound C1C(O)CN(C(=O)CC=2C=CC(F)=CC=2)N1C(=O)OCC1=CC=CC=C1 ZUTIOUJGTRXZOF-UHFFFAOYSA-N 0.000 description 2
- XXIWUZKNXKXZBD-UHFFFAOYSA-N benzyl 4-(2,2-dimethylpropanoyloxy)-2-[2-(4-fluorophenyl)acetyl]pyrazolidine-1-carboxylate Chemical compound C1C(OC(=O)C(C)(C)C)CN(C(=O)CC=2C=CC(F)=CC=2)N1C(=O)OCC1=CC=CC=C1 XXIWUZKNXKXZBD-UHFFFAOYSA-N 0.000 description 2
- UYUGVAGKAKJIOZ-UHFFFAOYSA-N benzyl 4-(2,2-dimethylpropanoyloxy)pyrazolidine-1-carboxylate Chemical compound C1C(OC(=O)C(C)(C)C)CNN1C(=O)OCC1=CC=CC=C1 UYUGVAGKAKJIOZ-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- IDXMZCVTPNXTBD-UHFFFAOYSA-N methyl 2-methylsulfanylpyrimidine-4-carboxylate Chemical compound COC(=O)C1=CC=NC(SC)=N1 IDXMZCVTPNXTBD-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- OKBMCNHOEMXPTM-UHFFFAOYSA-M potassium peroxymonosulfate Chemical compound [K+].OOS([O-])(=O)=O OKBMCNHOEMXPTM-UHFFFAOYSA-M 0.000 description 2
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 2
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- MKHMTFCUXVWWMM-UHFFFAOYSA-N trifluoromethyl 2-phenylacetate Chemical compound FC(F)(F)OC(=O)CC1=CC=CC=C1 MKHMTFCUXVWWMM-UHFFFAOYSA-N 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- RQEUFEKYXDPUSK-ZETCQYMHSA-N (1S)-1-phenylethanamine Chemical compound C[C@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-ZETCQYMHSA-N 0.000 description 1
- VFNVJVXCTYVZEU-ZBHICJROSA-N (2s)-2-amino-3-methylpentan-3-ol Chemical compound CCC(C)(O)[C@H](C)N VFNVJVXCTYVZEU-ZBHICJROSA-N 0.000 description 1
- OVKDLPZRDQTOJW-BYPYZUCNSA-N (3s)-3-amino-2-methylbutan-2-ol Chemical compound C[C@H](N)C(C)(C)O OVKDLPZRDQTOJW-BYPYZUCNSA-N 0.000 description 1
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- SJXRZXDWZBNBFB-UHFFFAOYSA-N 1-[4-(dimethylamino)-2-(2-methylsulfanylpyrimidine-4-carbonyl)pyrazolidin-1-yl]-2-(4-fluorophenyl)ethanone Chemical compound CSC1=NC=CC(C(=O)N2N(CC(C2)N(C)C)C(=O)CC=2C=CC(F)=CC=2)=N1 SJXRZXDWZBNBFB-UHFFFAOYSA-N 0.000 description 1
- JFBLEDVRFCFEQA-UHFFFAOYSA-N 1-o-benzyl 2-o-tert-butyl 4-hydroxypyrazolidine-1,2-dicarboxylate Chemical compound CC(C)(C)OC(=O)N1CC(O)CN1C(=O)OCC1=CC=CC=C1 JFBLEDVRFCFEQA-UHFFFAOYSA-N 0.000 description 1
- GJHJDXWVXVNIET-UHFFFAOYSA-N 1-o-benzyl 2-o-tert-butyl 4-oxopyrazolidine-1,2-dicarboxylate Chemical compound CC(C)(C)OC(=O)N1CC(=O)CN1C(=O)OCC1=CC=CC=C1 GJHJDXWVXVNIET-UHFFFAOYSA-N 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- STKARFFXWORTNB-UHFFFAOYSA-N 2,3-dihydro-1h-pyrazolo[1,2-a]pyrazol-5-one Chemical group C1CCN2C(=O)C=CN21 STKARFFXWORTNB-UHFFFAOYSA-N 0.000 description 1
- OUBZTWAVXMBDAY-UHFFFAOYSA-N 2-(4-fluorophenyl)-1-(4-morpholin-4-ylpyrazolidin-1-yl)ethanone Chemical compound C1=CC(F)=CC=C1CC(=O)N1NCC(N2CCOCC2)C1 OUBZTWAVXMBDAY-UHFFFAOYSA-N 0.000 description 1
- MGKPFALCNDRSQD-UHFFFAOYSA-N 2-(4-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C(F)C=C1 MGKPFALCNDRSQD-UHFFFAOYSA-N 0.000 description 1
- SIOJFYRPBYGHOO-UHFFFAOYSA-N 2-(4-fluorophenyl)acetyl chloride Chemical compound FC1=CC=C(CC(Cl)=O)C=C1 SIOJFYRPBYGHOO-UHFFFAOYSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- VXFMVTHYCGTCHL-UHFFFAOYSA-N 2-methylsulfonylpyrimidine-4-carbonyl chloride Chemical compound CS(=O)(=O)C1=NC=CC(C(Cl)=O)=N1 VXFMVTHYCGTCHL-UHFFFAOYSA-N 0.000 description 1
- UVPBTBMYZNTBRY-UHFFFAOYSA-N 2-o-benzyl 1-o-tert-butyl pyrazolidine-1,2-dicarboxylate Chemical compound CC(C)(C)OC(=O)N1CCCN1C(=O)OCC1=CC=CC=C1 UVPBTBMYZNTBRY-UHFFFAOYSA-N 0.000 description 1
- 125000001698 2H-pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003974 3-carbamimidamidopropyl group Chemical group C(N)(=N)NCCC* 0.000 description 1
- XJFZOSUFGSANIF-UHFFFAOYSA-N 3-chloro-2-(chloromethyl)prop-1-ene Chemical compound ClCC(=C)CCl XJFZOSUFGSANIF-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- ZZIXNGRDILYTIK-UHFFFAOYSA-N 3-methylpyrazolidine Chemical compound CC1CCNN1 ZZIXNGRDILYTIK-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- ODNGOAPHEURWTK-UHFFFAOYSA-N 4-hydroxypyrazolidine-1,2-dicarboxylic acid Chemical compound OC1CN(C(O)=O)N(C(O)=O)C1 ODNGOAPHEURWTK-UHFFFAOYSA-N 0.000 description 1
- SEACIKUEQAKYAB-UHFFFAOYSA-N 4-methoxypyrazolidine-1,2-dicarboxylic acid Chemical compound COC1CN(C(O)=O)N(C(O)=O)C1 SEACIKUEQAKYAB-UHFFFAOYSA-N 0.000 description 1
- LLUBGQYWZMYAFK-UHFFFAOYSA-N 4-oxo-2-phenylmethoxycarbonylpyrazolidine-1-carboxylic acid Chemical compound OC(=O)N1CC(=O)CN1C(=O)OCC1=CC=CC=C1 LLUBGQYWZMYAFK-UHFFFAOYSA-N 0.000 description 1
- UWWFWMBQAWGKCN-UHFFFAOYSA-N 6-(4-fluorophenyl)-7-(2-methylsulfanylpyrimidin-4-yl)-2,3-dihydro-1h-pyrazolo[1,2-a]pyrazol-5-one Chemical compound CSC1=NC=CC(C=2N3CCCN3C(=O)C=2C=2C=CC(F)=CC=2)=N1 UWWFWMBQAWGKCN-UHFFFAOYSA-N 0.000 description 1
- HLPJRLLPIGPREM-UHFFFAOYSA-N 6-(4-fluorophenyl)-7-[2-(2-methyl-2-phenylhydrazinyl)pyrimidin-4-yl]-2,3-dihydro-1h-pyrazolo[1,2-a]pyrazol-5-one Chemical compound C=1C=CC=CC=1N(C)NC(N=1)=NC=CC=1C(N1CCCN1C1=O)=C1C1=CC=C(F)C=C1 HLPJRLLPIGPREM-UHFFFAOYSA-N 0.000 description 1
- LSXDMSPDXVTUDM-KRWDZBQOSA-N 6-(4-fluorophenyl)-7-[2-[[(1s)-1-(4-methylphenyl)ethyl]amino]pyrimidin-4-yl]-2,3-dihydro-1h-pyrazolo[1,2-a]pyrazol-5-one Chemical compound N([C@@H](C)C=1C=CC(C)=CC=1)C(N=1)=NC=CC=1C(N1CCCN1C1=O)=C1C1=CC=C(F)C=C1 LSXDMSPDXVTUDM-KRWDZBQOSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010024503 Limb reduction defect Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001134446 Niveas Species 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- JKFMTCOZPDABJG-UHFFFAOYSA-N [1-[2-(4-fluorophenyl)acetyl]pyrazolidin-4-yl] morpholine-4-carboxylate Chemical compound C1=CC(F)=CC=C1CC(=O)N1NCC(OC(=O)N2CCOCC2)C1 JKFMTCOZPDABJG-UHFFFAOYSA-N 0.000 description 1
- WBBIMWOSWDKRCD-UHFFFAOYSA-N [6-(4-fluorophenyl)-7-(2-methylsulfanylpyrimidin-4-yl)-5-oxo-2,3-dihydro-1h-pyrazolo[1,2-a]pyrazol-2-yl] 2,2-dimethylpropanoate Chemical compound CSC1=NC=CC(C=2N3CC(CN3C(=O)C=2C=2C=CC(F)=CC=2)OC(=O)C(C)(C)C)=N1 WBBIMWOSWDKRCD-UHFFFAOYSA-N 0.000 description 1
- 125000004054 acenaphthylenyl group Chemical group C1(=CC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- FIVIYCCIEIIOSA-UHFFFAOYSA-N benzyl 2-[2-(4-fluorophenyl)acetyl]-4-(4-nitrophenoxy)carbonyloxypyrazolidine-1-carboxylate Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC(=O)OC1CN(C(=O)OCC=2C=CC=CC=2)N(C(=O)CC=2C=CC(F)=CC=2)C1 FIVIYCCIEIIOSA-UHFFFAOYSA-N 0.000 description 1
- SBXLAJWMWLOZET-UHFFFAOYSA-N benzyl n-[(2-methylpropan-2-yl)oxycarbonylamino]carbamate Chemical compound CC(C)(C)OC(=O)NNC(=O)OCC1=CC=CC=C1 SBXLAJWMWLOZET-UHFFFAOYSA-N 0.000 description 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- BVCRERJDOOBZOH-UHFFFAOYSA-N bicyclo[2.2.1]heptanyl Chemical group C1C[C+]2CC[C-]1C2 BVCRERJDOOBZOH-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- AJPPKGMEHMXPMC-UHFFFAOYSA-N methyl 2-(4-fluorophenyl)acetate Chemical compound COC(=O)CC1=CC=C(F)C=C1 AJPPKGMEHMXPMC-UHFFFAOYSA-N 0.000 description 1
- DNRVPMNRFYJZBV-UHFFFAOYSA-N methyl 2-methyl-5-sulfanylpyrimidine-4-carboxylate Chemical compound COC(=O)C1=NC(C)=NC=C1S DNRVPMNRFYJZBV-UHFFFAOYSA-N 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 125000003585 oxepinyl group Chemical group 0.000 description 1
- 125000005646 oximino group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 229940018489 pronto Drugs 0.000 description 1
- LSEKLPKUWRDLKY-UHFFFAOYSA-N protoleucomelone Chemical compound C1=CC(OC(=O)C)=CC=C1C1=C(OC(C)=O)C(OC(C)=O)=C(C=2C(=CC(OC(C)=O)=C(OC(C)=O)C=2)O2)C2=C1OC(C)=O LSEKLPKUWRDLKY-UHFFFAOYSA-N 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 229910001923 silver oxide Inorganic materials 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- NESLWCLHZZISNB-UHFFFAOYSA-M sodium phenolate Chemical compound [Na+].[O-]C1=CC=CC=C1 NESLWCLHZZISNB-UHFFFAOYSA-M 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- GRONZTPUWOOUFQ-UHFFFAOYSA-M sodium;methanol;hydroxide Chemical compound [OH-].[Na+].OC GRONZTPUWOOUFQ-UHFFFAOYSA-M 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/20—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32362501P | 2001-09-20 | 2001-09-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200401260B true ZA200401260B (en) | 2004-08-30 |
Family
ID=23259997
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200401260A ZA200401260B (en) | 2001-09-20 | 2004-02-17 | 6,7-dihydro-5h-pyrazol(1,2-a)pyrazol-1-ones which control inflammatory cytokines. |
| ZA200401402A ZA200401402B (en) | 2001-09-20 | 2004-02-20 | Spirocyclic-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines. |
| ZA200401403A ZA200401403B (en) | 2001-09-20 | 2004-02-20 | Compounds which inhibit the release of inflamatory cytokines. |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200401402A ZA200401402B (en) | 2001-09-20 | 2004-02-20 | Spirocyclic-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines. |
| ZA200401403A ZA200401403B (en) | 2001-09-20 | 2004-02-20 | Compounds which inhibit the release of inflamatory cytokines. |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US6821971B2 (hu) |
| EP (3) | EP1427732B1 (hu) |
| JP (3) | JP2005504082A (hu) |
| KR (4) | KR20040035837A (hu) |
| CN (3) | CN1257905C (hu) |
| AR (3) | AR037502A1 (hu) |
| AT (3) | ATE332901T1 (hu) |
| AU (2) | AU2002334641B2 (hu) |
| BR (3) | BR0212716A (hu) |
| CA (3) | CA2461072A1 (hu) |
| CO (3) | CO5560590A2 (hu) |
| CY (1) | CY1106398T1 (hu) |
| CZ (3) | CZ2004345A3 (hu) |
| DE (3) | DE60218704T2 (hu) |
| DK (2) | DK1427732T3 (hu) |
| EG (2) | EG24413A (hu) |
| ES (3) | ES2282459T3 (hu) |
| HK (2) | HK1071366A1 (hu) |
| HU (3) | HUP0402378A3 (hu) |
| IL (3) | IL160742A0 (hu) |
| MA (3) | MA27065A1 (hu) |
| MX (3) | MXPA04002570A (hu) |
| MY (2) | MY129069A (hu) |
| NO (2) | NO20041594L (hu) |
| NZ (3) | NZ531063A (hu) |
| PE (3) | PE20030446A1 (hu) |
| PL (3) | PL370415A1 (hu) |
| PT (3) | PT1427732E (hu) |
| RU (3) | RU2272040C2 (hu) |
| SA (1) | SA03230529B1 (hu) |
| SK (3) | SK1502004A3 (hu) |
| WO (3) | WO2003024971A1 (hu) |
| ZA (3) | ZA200401260B (hu) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6849627B2 (en) | 2001-09-20 | 2005-02-01 | The Procter & Gamble Company | 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines |
| US7087615B2 (en) | 2001-09-20 | 2006-08-08 | The Procter & Gamble Company | 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which provide analgesia |
| US6730668B2 (en) * | 2001-09-20 | 2004-05-04 | The Procter & Gamble Company | 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines |
| US7473695B2 (en) | 2001-10-22 | 2009-01-06 | Mitsubishi Tanabe Pharma Corporation | 4-imidazolin-2-one compounds |
| US6677337B2 (en) * | 2002-03-19 | 2004-01-13 | The Procter & Gamble Company | 1,2-dihydropyrazol-3-ones which controls inflammatory cytokines |
| EP1542680B1 (en) * | 2002-09-09 | 2007-03-07 | Amgen Inc. | 1, 4, 5-substituted 1, 2-dihydro-pyrazol-3-one and 3-alkoxy-1h-pyrazole derivatives as tnf-alpha and interleukin lowering agents for the treatment of inflammations |
| KR20050109617A (ko) * | 2003-04-03 | 2005-11-21 | 메르크 파텐트 게엠베하 | 혈전증 치료용 응집 인자 ｘａ 저해제로서의피라졸리딘-１,２-디카르복실디페닐아미드 유도체 |
| GB0308466D0 (en) | 2003-04-11 | 2003-05-21 | Novartis Ag | Organic compounds |
| US7482356B2 (en) * | 2003-11-10 | 2009-01-27 | The Procter & Gamble Company | Bicyclic pyrazolone cytokine inhibitors |
| NZ571706A (en) * | 2006-04-18 | 2012-06-29 | Abbott Lab | Antagonists of the vanilloid receptor subtype 1 (VR1) and uses thereof |
| DE102008060549A1 (de) | 2008-12-04 | 2010-06-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung |
| ES2417355T3 (es) * | 2009-05-19 | 2013-08-07 | Dow Agrosciences Llc | Compuestos y métodos para el control de hongos |
| CN107636366B (zh) | 2015-06-15 | 2021-03-12 | 卡明斯公司 | 燃烧室弹性装置 |
| US20190060286A1 (en) | 2016-02-29 | 2019-02-28 | University Of Florida Research Foundation, Incorpo | Chemotherapeutic Methods |
| CN107033090B (zh) * | 2017-05-16 | 2019-05-07 | 无锡捷化医药科技有限公司 | 一种1,2,3,4-四氢噌啉的制备方法 |
| RU2721684C1 (ru) * | 2019-09-06 | 2020-05-21 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" | Метил 2,3,8-триоксо-4-фенилтетрагидро-6Н-пиразоло[1,2-а]пирроло[2,3-c]пиразол-9а(1Н)-карбоксилаты |
| EP4422621A1 (en) * | 2021-10-27 | 2024-09-04 | Merck Sharp & Dohme LLC | Spirotricycle ripk1 inhibitors and methods of uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1054291A (hu) | 1963-02-26 | |||
| GB1124982A (en) * | 1965-02-09 | 1968-08-21 | Lepetit Spa | Diazabicyclo octanes and derivatives thereof |
| CH529154A (fr) | 1969-10-27 | 1972-10-15 | Lepetit Spa | Procédé de préparation de pyrazolo (1,2-b) phtalazine-1,5 (10H)-diones |
| US5358924A (en) * | 1991-03-21 | 1994-10-25 | Bayer Aktiengesellschaft | 3-hydroxy-4-aryl-5-oxo-pyrozoline derivatives, compositions and use |
| EP1481970B1 (de) * | 1999-09-07 | 2006-03-22 | Syngenta Participations AG | Neue Herbizide |
| US6730668B2 (en) * | 2001-09-20 | 2004-05-04 | The Procter & Gamble Company | 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines |
-
2002
- 2002-09-18 US US10/245,927 patent/US6821971B2/en not_active Expired - Fee Related
- 2002-09-18 US US10/246,499 patent/US6566357B1/en not_active Expired - Fee Related
- 2002-09-20 AU AU2002334641A patent/AU2002334641B2/en not_active Expired - Fee Related
- 2002-09-20 NZ NZ531063A patent/NZ531063A/en not_active IP Right Cessation
- 2002-09-20 JP JP2003528818A patent/JP2005504082A/ja active Pending
- 2002-09-20 BR BR0212716-4A patent/BR0212716A/pt not_active IP Right Cessation
- 2002-09-20 IL IL16074202A patent/IL160742A0/xx unknown
- 2002-09-20 CA CA002461072A patent/CA2461072A1/en not_active Abandoned
- 2002-09-20 SK SK150-2004A patent/SK1502004A3/sk unknown
- 2002-09-20 PL PL02370415A patent/PL370415A1/xx not_active Application Discontinuation
- 2002-09-20 ES ES02763693T patent/ES2282459T3/es not_active Expired - Lifetime
- 2002-09-20 RU RU2004111806/04A patent/RU2272040C2/ru not_active IP Right Cessation
- 2002-09-20 AR ARP020103549A patent/AR037502A1/es not_active Application Discontinuation
- 2002-09-20 DK DK02799017T patent/DK1427732T3/da active
- 2002-09-20 AT AT02799017T patent/ATE332901T1/de not_active IP Right Cessation
- 2002-09-20 PL PL02370362A patent/PL370362A1/xx not_active Application Discontinuation
- 2002-09-20 EP EP02799017A patent/EP1427732B1/en not_active Expired - Lifetime
- 2002-09-20 PT PT02799017T patent/PT1427732E/pt unknown
- 2002-09-20 MX MXPA04002570A patent/MXPA04002570A/es active IP Right Grant
- 2002-09-20 AU AU2002327690A patent/AU2002327690B2/en not_active Ceased
- 2002-09-20 CN CNB028182286A patent/CN1257905C/zh not_active Expired - Fee Related
- 2002-09-20 AT AT02763693T patent/ATE356126T1/de not_active IP Right Cessation
- 2002-09-20 PL PL02370351A patent/PL370351A1/xx not_active Application Discontinuation
- 2002-09-20 CN CNB028182294A patent/CN1250551C/zh not_active Expired - Fee Related
- 2002-09-20 RU RU2004111805/04A patent/RU2278864C2/ru active
- 2002-09-20 PE PE2002000924A patent/PE20030446A1/es not_active Application Discontinuation
- 2002-09-20 BR BR0212905-1A patent/BR0212905A/pt not_active IP Right Cessation
- 2002-09-20 PT PT02763692T patent/PT1427727E/pt unknown
- 2002-09-20 CZ CZ2004345A patent/CZ2004345A3/cs unknown
- 2002-09-20 SK SK149-2004A patent/SK1492004A3/sk unknown
- 2002-09-20 CZ CZ2004361A patent/CZ2004361A3/cs unknown
- 2002-09-20 EP EP02763692A patent/EP1427727B1/en not_active Expired - Lifetime
- 2002-09-20 ES ES02799017T patent/ES2268154T3/es not_active Expired - Lifetime
- 2002-09-20 DE DE60218704T patent/DE60218704T2/de not_active Expired - Lifetime
- 2002-09-20 PE PE2002000925A patent/PE20030474A1/es not_active Application Discontinuation
- 2002-09-20 CZ CZ2004358A patent/CZ2004358A3/cs unknown
- 2002-09-20 JP JP2003528817A patent/JP2005504081A/ja active Pending
- 2002-09-20 WO PCT/US2002/030135 patent/WO2003024971A1/en active IP Right Grant
- 2002-09-20 DE DE60202782T patent/DE60202782T2/de not_active Expired - Lifetime
- 2002-09-20 IL IL16074102A patent/IL160741A0/xx unknown
- 2002-09-20 KR KR10-2004-7004046A patent/KR20040035837A/ko not_active Application Discontinuation
- 2002-09-20 DE DE60213108T patent/DE60213108T2/de not_active Expired - Fee Related
- 2002-09-20 EP EP02763693A patent/EP1427728B1/en not_active Expired - Lifetime
- 2002-09-20 PT PT02763693T patent/PT1427728E/pt unknown
- 2002-09-20 IL IL16068202A patent/IL160682A0/xx unknown
- 2002-09-20 BR BR0212673-7A patent/BR0212673A/pt not_active IP Right Cessation
- 2002-09-20 KR KR1020067006983A patent/KR20060036125A/ko not_active Application Discontinuation
- 2002-09-20 NZ NZ531122A patent/NZ531122A/en unknown
- 2002-09-20 MX MXPA04002569A patent/MXPA04002569A/es active IP Right Grant
- 2002-09-20 CA CA002461071A patent/CA2461071A1/en not_active Abandoned
- 2002-09-20 NZ NZ531123A patent/NZ531123A/en not_active IP Right Cessation
- 2002-09-20 ES ES02763692T patent/ES2237691T3/es not_active Expired - Lifetime
- 2002-09-20 HU HU0402378A patent/HUP0402378A3/hu unknown
- 2002-09-20 RU RU2004111803/04A patent/RU2299885C2/ru active
- 2002-09-20 PE PE2002000923A patent/PE20030430A1/es not_active Application Discontinuation
- 2002-09-20 CN CNB028183800A patent/CN1249066C/zh not_active Expired - Fee Related
- 2002-09-20 HU HU0402500A patent/HUP0402500A3/hu unknown
- 2002-09-20 CA CA002461073A patent/CA2461073A1/en not_active Abandoned
- 2002-09-20 WO PCT/US2002/030133 patent/WO2003024973A1/en not_active Application Discontinuation
- 2002-09-20 KR KR1020047004045A patent/KR100623879B1/ko not_active IP Right Cessation
- 2002-09-20 MX MXPA04002574A patent/MXPA04002574A/es active IP Right Grant
- 2002-09-20 AR ARP020103548A patent/AR037145A1/es unknown
- 2002-09-20 JP JP2003528820A patent/JP2005504083A/ja active Pending
- 2002-09-20 MY MYPI20023502A patent/MY129069A/en unknown
- 2002-09-20 KR KR1020047004043A patent/KR100656126B1/ko not_active IP Right Cessation
- 2002-09-20 WO PCT/US2002/030134 patent/WO2003024970A1/en active IP Right Grant
- 2002-09-20 MY MYPI20023518A patent/MY129329A/en unknown
- 2002-09-20 SK SK148-2004A patent/SK1482004A3/sk unknown
- 2002-09-20 HU HU0500752A patent/HUP0500752A2/hu unknown
- 2002-09-20 AT AT02763692T patent/ATE287887T1/de not_active IP Right Cessation
- 2002-09-20 DK DK02763693T patent/DK1427728T3/da active
- 2002-09-20 AR ARP020103550A patent/AR037237A1/es not_active Application Discontinuation
- 2002-09-21 EG EG2002091039A patent/EG24413A/xx active
- 2002-09-21 EG EG2002091037A patent/EG24363A/xx active
-
2003
- 2003-01-26 SA SA3230529A patent/SA03230529B1/ar unknown
-
2004
- 2004-02-17 ZA ZA200401260A patent/ZA200401260B/en unknown
- 2004-02-20 ZA ZA200401402A patent/ZA200401402B/en unknown
- 2004-02-20 ZA ZA200401403A patent/ZA200401403B/en unknown
- 2004-03-09 CO CO04021425A patent/CO5560590A2/es not_active Application Discontinuation
- 2004-03-09 CO CO04021424A patent/CO5560589A2/es not_active Application Discontinuation
- 2004-03-10 MA MA27568A patent/MA27065A1/fr unknown
- 2004-03-10 MA MA27567A patent/MA27064A1/fr unknown
- 2004-03-10 MA MA27569A patent/MA27066A1/fr unknown
- 2004-03-12 CO CO04023010A patent/CO5560579A2/es not_active Application Discontinuation
- 2004-04-19 NO NO20041594A patent/NO20041594L/no not_active Application Discontinuation
- 2004-04-20 NO NO20041605A patent/NO20041605L/no not_active Application Discontinuation
-
2005
- 2005-05-18 HK HK05104163A patent/HK1071366A1/xx not_active IP Right Cessation
- 2005-05-24 HK HK05104374A patent/HK1071565A1/xx not_active IP Right Cessation
-
2007
- 2007-03-20 CY CY20071100383T patent/CY1106398T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200401260B (en) | 6,7-dihydro-5h-pyrazol(1,2-a)pyrazol-1-ones which control inflammatory cytokines. | |
| WO2007046548A1 (en) | Pyrazolo[1,5-a]pyrimidine compounds as cannabinoid receptor antagonists | |
| JP2008285464A (ja) | ピラゾロ［１，５−ａ］ピリミジン化合物 | |
| US7368455B2 (en) | 6,7-Dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines | |
| TWI228416B (en) | Cyano-substituted dihydropyrimidine compounds and their use to treat diseases | |
| AU2002327690A1 (en) | 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines | |
| JP2008007493A (ja) | ピラゾロ［１，５−ａ］ピリミジン化合物 | |
| AU2003220216A1 (en) | 1,2-dihydropyrazol-3-ones as cytokine mediators | |
| US7326714B2 (en) | 6,7-Dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines | |
| US6849627B2 (en) | 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines |